My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    PF-1355
    PF-1355

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V4426
    CAS #: 1435467-38-1Purity ≥98%

    Description: PF-1355 (also known as PF-06281355), a 2-thiouracil analog, is a novel, potent, selective and orally bioavailable mechanism-based MPO inhibitor  used for treatment of vasculitic diseases. MPO is a critical mediator of vasculitis in mouse disease models. MPO has been associated with vasculitis, disseminated vascular inflammation typically involving pulmonary and renal microvasculature and often resulting in critical consequences. MPO contributes to vascular injury by 1) catabolizing nitric oxide, impairing vasomotor function; 2) causing oxidative damage to lipoproteins and endothelial cells, leading to atherosclerosis; and 3) stimulating formation of neutrophil extracellular traps, resulting in vessel occlusion and thrombosis.  A pharmacokinetic/pharmacodynamic response model of PF-1355 exposure in relation with MPO activity was derived from mouse peritonitis. The contribution of MPO activity to vasculitis was then examined in an immune complex model of pulmonary disease. Oral administration of PF-1355 reduced plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Goodpasture disease, albuminuria and chronic renal dysfunction were completely suppressed by PF-1355treatment. This study shows that MPO activity is critical in driving immune complex vasculitis and provides confidence in testing the hypothesis that MPO inhibition will provide benefit in treating human vasculitic diseases. 

    References:  2015 May;353(2):288-98. 


    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
     

    PF-1355

    Name: PF-06281355
    CAS#: 1435467-38-1
    Chemical Formula: C14H15N3O4S
    Exact Mass: 321.0783
    Molecular Weight: 321.351
    Elemental Analysis: C, 52.33; H, 4.71; N, 13.08; O, 19.91; S, 9.98
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Technical InformationSynonym: PF-1355; PF 1355; PF1355; PF-06281355; PF 06281355; PF06281355;
    IUPAC/Chemical Name: 2-(6-(2,5-Dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide
    InChi Key: LJBUZOGABRDGBR-UHFFFAOYSA-N
    InChi Code: InChI=1S/C14H15N3O4S/c1-20-8-3-4-11(21-2)9(5-8)10-6-13(19)16-14(22)17(10)7-12(15)18/h3-6H,7H2,1-2H3,(H2,15,18)(H,16,19,22)
    SMILES Code: O=C(N)CN(C(N1)=S)C(C2=CC(OC)=CC=C2OC)=CC1=O


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2

    These protocols are for reference only. InvivoChem does not independently validate these methods.

     PF-1355


    Determination of potency and reversibility of PF-1355 for MPO inhibition.  2015 May;353(2):288-98.

     PF-1355


    PF-1355 and MPO deficiency protects in immune complex–induced pulmonary vasculitis.  2015 May;353(2):288-98.

    PF-1355

    Establishing a pharmacokinetic/pharmacodynamic relationship between plasma [PF-1355] and MPO inhibition in a mouse peritonitis model.

     PF-1355


    MPO activity is essential for disease induction in a model of anti-GBM glomerulonephritis.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?